Mechanism of Inflammatory Related Brain Dysfunction after Spinal Cord Injury
脊髓损伤后炎症相关脑功能障碍的机制
基本信息
- 批准号:10380183
- 负责人:
- 金额:$ 43.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAdultAffectAgreementAlzheimer&aposs DiseaseAnti-Inflammatory AgentsAntibodiesAttenuatedAutonomic DysfunctionAxonBasic ScienceBehaviorBrainBrain regionCSF1R geneCXCR3 geneCerebral cortexChronicClinical TrialsCognitionCognition DisordersCognitiveCraniocerebral TraumaCysteineDataDementiaDevelopmentFutureGeneticHippocampus (Brain)ITGAM geneImpaired cognitionImpairmentIn VitroInflammationInflammatoryInflammatory ResponseInjectionsInjuryInterventionLearningLigandsLinkMediatingMemoryMental DepressionMessenger RNAMicrogliaModelingMolecularMolecular GeneticsMood DisordersMoodsMotorMusNerve DegenerationNeuronal InjuryNeuropsychological TestsNeuropsychologyPatient Self-ReportPatientsPerformancePharmaceutical PreparationsPharmacologyPilot ProjectsQuality of lifeRattusRecombinant ProteinsRecording of previous eventsRecoveryRecovery of FunctionRehabilitation therapyReportingResearchRiskRoleSpinal Cord LesionsSpinal cord injurySpinal cord injury patientsSynapsesTestingThalamic structureTherapeutic InterventionTransgenic MiceUp-RegulationWorkantagonistbrain dysfunctionbrain parenchymabrain tissuechemokinecognitive recoverycytokinedementia riskdepressive symptomseffective interventionfall riskfunctional outcomesgene therapygenetic approachhigh riskimprovedin vivomotor disorderneuroinflammationneuronal survivalneuropsychiatrynovel therapeuticspainful neuropathyprogressive neurodegenerationreceptorspinal cord and brain injurytargeted treatment
项目摘要
Project Summary
Neuropsychological deficits have been reported after spinal cord injury (SCI) without concurrent head injury;
although most such studies reflect patient self-reports, more formal neuropsychological testing has
demonstrated performance impairments with an associated high risk of dementia including deficits in learning
and memory. On the other hand, patients with dementia, such as that resulting from Alzheimer’s disease (AD),
could have higher risk of falls, and therefore increased risk of SCI. Little research has addressed potential
mechanisms for such neuropsychiatric changes or their implications for targeted therapy. There is an urgent
need for such studies, as posttraumatic dementia such as cognitive and psychiatric changes negatively impact
rehabilitation and impair recovery. The purpose of this study is to identify the mechanisms responsible for
these less well examined yet important consequences of SCI and test the hypothesis that SCI-triggered
release of CCL21 in the brain contributes to spreading neuroinflammation with cognitive dysfunction and
depressive-like behavior, which can be improved by targeting specific mechanisms of neuroinflammation.
We will use transgenic mice and molecular interventions to delineate the role of CCL21 as a key
regulator of brain microglial activation and related down-stream injury mechanisms in SCI. Aim 1 will identify
that SCI-induced CCL21 elevation mediates detrimental microglial activation in the brain
through NOX2 activity. Multiple quantitative assessments of microglia activation will be combined with a
molecular/genetic intervention targeting CCL21 to test the hypothesis that SCI-induced release of CCL21 in
key regions of the brain contributes to detrimental microglial activation through NOX2 activity. Aim 2 will
demonstrate that genetic depletion or pharmacological inhibition of CCL21/NOX2 reduces
detrimental microglial activation, resulting in improved cognitive decline and depressive-like
behavior. Complimentary pharmacological, molecular, and genetic approaches will be used to test the
hypothesis that brain CCL21/NOX2-mediated inflammation after SCI causes chronic neurodegeneration
associated with cognitive decline and depressive-like behavior. Aim 3 will determine that genetic or
pharmacological microglial ablation after SCI reduces brain neuroinflammation leading to
improved functional recovery. Using genetic or pharmacological microglia-deletion, we will examine the
role of resident microglia in SCI-mediated neuroinflammation in the brain and functional outcomes.
The information gained from these studies would have an important positive impact by identifying the
key mechanisms involved in important yet largely ignored brain changes after SCI and identifying potential
therapeutic interventions.
项目摘要
据报道,脊髓损伤(SCI)后,没有并发头部损伤的神经心理缺陷;
虽然大多数此类研究反映了患者的自我报告,但更正式的神经心理学测试
表现出与痴呆症相关的高风险表现障碍,包括学习缺陷
和记忆另一方面,患有痴呆症的患者,例如由阿尔茨海默病(AD)引起的患者,
可能有更高的福尔斯风险,因此增加了SCI的风险。很少有研究涉及潜在的
这种神经精神变化的机制或其对靶向治疗的影响。目前迫切
需要这样的研究,因为创伤后痴呆症,如认知和精神变化的负面影响
康复和损害恢复。这项研究的目的是确定负责的机制,
这些不太好的研究,但重要的后果SCI和测试的假设,SCI触发
大脑中CCL 21的释放有助于神经炎症的扩散和认知功能障碍,
抑郁样行为,这可以通过靶向神经炎症的特定机制来改善。
我们将使用转基因小鼠和分子干预来描述CCL 21作为一个关键的作用。
脊髓损伤中脑小胶质细胞活化的调节因子及相关的下游损伤机制目标1将确定
SCI诱导的CCL 21升高介导了大脑中有害的小胶质细胞活化,
NOX 2活性。对小胶质细胞活化的多项定量评估将与
靶向CCL 21的分子/遗传干预,以检验SCI诱导的CCL 21释放的假设。
大脑的关键区域通过NOX 2活性促进有害的小胶质细胞活化。目标2将
证明了CCL 21/NOX 2的遗传耗竭或药理学抑制降低了
有害的小胶质细胞激活,导致改善认知能力下降和抑郁样
行为将使用免费的药理学、分子学和遗传学方法来检测
SCI后脑CCL 21/NOX 2介导炎症导致慢性神经退行性变假说
与认知能力下降和抑郁样行为有关。目标3将决定基因或
SCI后的药物小胶质细胞消融减少了脑神经炎症,
改善功能恢复。使用遗传学或药理学小胶质细胞缺失,我们将检查
常驻小胶质细胞在SCI介导的脑神经炎症和功能结局中的作用。
从这些研究中获得的信息将产生重要的积极影响,
SCI后重要但在很大程度上被忽视的大脑变化的关键机制,
治疗干预。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN Ira FADEN其他文献
ALAN Ira FADEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN Ira FADEN', 18)}}的其他基金
Bidirectional Brain-Gut interactions, chronic neuroinflammation and neurodegeneration after traumatic brain injury
双向脑肠相互作用、脑外伤后慢性神经炎症和神经退行性变
- 批准号:
10684129 - 财政年份:2022
- 资助金额:
$ 43.16万 - 项目类别:
Bidirectional Brain-Gut interactions, chronic neuroinflammation and neurodegeneration after traumatic brain injury
双向脑肠相互作用、脑外伤后慢性神经炎症和神经退行性变
- 批准号:
10517782 - 财政年份:2022
- 资助金额:
$ 43.16万 - 项目类别:
Mechanism of Inflammatory Related Brain Dysfunction after Spinal Cord Injury
脊髓损伤后炎症相关脑功能障碍的机制
- 批准号:
10597985 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Reprogramming Microglial Epigenetic Pathways to Promote Cognitive Recovery after Brain Trauma.
重新编程小胶质细胞表观遗传途径以促进脑外伤后的认知恢复。
- 批准号:
10381618 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Reprogramming Microglial Epigenetic Pathways to Promote Cognitive Recovery after Brain Trauma.
重新编程小胶质细胞表观遗传途径以促进脑外伤后的认知恢复。
- 批准号:
9884830 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Reprogramming Microglial Epigenetic Pathways to Promote Cognitive Recovery after Brain Trauma.
重新编程小胶质细胞表观遗传途径以促进脑外伤后的认知恢复。
- 批准号:
10596517 - 财政年份:2019
- 资助金额:
$ 43.16万 - 项目类别:
Role of miR-23a/27 a in secondary injury after TBI
miR-23a/27a在TBI后继发性损伤中的作用
- 批准号:
9332481 - 财政年份:2015
- 资助金额:
$ 43.16万 - 项目类别:
Role of miR-23a/27 a in secondary injury after TBI
miR-23a/27a在TBI后继发性损伤中的作用
- 批准号:
9760010 - 财政年份:2015
- 资助金额:
$ 43.16万 - 项目类别:
Mechanisms and Modulation of Cell Death in Traumatic Brain Injury
创伤性脑损伤中细胞死亡的机制和调节
- 批准号:
8090307 - 财政年份:2009
- 资助金额:
$ 43.16万 - 项目类别:
Combination drug treatment to inhibit multiple cell death pathways after TBI
抑制 TBI 后多种细胞死亡途径的联合药物治疗
- 批准号:
7985713 - 财政年份:2009
- 资助金额:
$ 43.16万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 43.16万 - 项目类别:
Research Grant